An observational study in Hyaluronic Acid, sponsored by Southeast University, China. Status unknown. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-24.
Sponsored by Southeast University, China · Observational
Maintaining the normal function of the pulmonary microvascular barrier is critical for ARDS treatment. To assess the relationship between the HAS2 protein level, HA content and the clinical prognosis of ARDS in patients with ARDS. Compare the HAS2 protein levels, HMW-HA and LMW-HA levels, endothelial injury indicators, and lungs in the blood of severe and non-ARDS severe patients and healthy adults admitted to the ICU. The correlation between permeability, disease severity and prognosis to explore the predictability of HAS2-HA on the clinical outcome of ARDS.
Southeast University, China is the lead sponsor of 164 studies on the registry; 44 are open to participants now.
Counted across the registry records on this site, refreshed daily.
1.85 years≥Age≥18 years. 2.Moderate-to-severe ARDS, defined by the ARDS Definition Task Force in the Berlin definition (partial pressure of arterial oxygen [PaO2]:FiO2 ratio ≤200 mmHg with a PEEP ≥5 cmH2O).
3.Diagnosis of ARDS less than 72 hours.
1.85 years≥Age≥18 years. 2.Moderate-to-severe ARDS, defined by the ARDS Definition Task Force in the Berlin definition (partial pressure of arterial oxygen [PaO2]:FiO2 ratio ≤200 mmHg with a PEEP ≥5 cmH2O).
3.Diagnosis of ARDS less than 72 hours.
Exclusion Criteria:
All patients who meet any of the following criteria will be excluded at enrollment and randomization.
1.85 years≥Age≥18 years. 2.Moderate-to-severe ARDS, defined by the ARDS Definition Task Force in the Berlin definition (partial pressure of arterial oxygen \[PaO2\]:FiO2 ratio ≤200 mmHg with a PEEP ≥5 cmH2O). 3.Diagnosis of ARDS less than 72 hours. 4.Just observation
Unstable vital signs, rapid changes in the condition, unstable function of more than two organ systems (excluding the respiratory system), decline or failure, the development of the disease may endanger the life of the patient.
Healthy adults, voluntarily join the study.
28-day fatality Rate
28-day mortality (patients will be followed for 28 days)
Time frame: 28 days after enrollment
90-day fatality rate
90-day mortality (patients will be followed for 90 days)
Time frame: 90 days after enrollment
ICU hospital stay
Length of ICU stay
Time frame: through study completion, an average of 4 week
ICU fatality rate
The ratio of the total number of deaths from all causes of the enrolled patients during ICU hospitalization.
Time frame: through study completion, an average of 4 week
Wearing time from mechanical ventilation
successful weaning defined as the absence of the requirement for ventilatory support, without reintubation
Time frame: through study completion，an average of 4 week
Peripheral blood HMW-HA and LMW-HA levels
ELISA method to separate and detect HMW-HA and LMW-HA levels（Units of Measure unit nM/ml）
Time frame: 0, 1, 3, 7 days after enrollment
HAS2 protein content in peripheral blood
ELISA method detects HAS2 protein in peripheral blood
Time frame: 0, 1, 3, 7 days after enrollment
ENOS, ET-1, vWF levels in peripheral blood
ELISA method to detect eNOS, ET-1, vWF in peripheral blood to evaluate endothelial cell damage（Measure unit ng/ml）
Time frame: 0, 1, 3, 7 days after enrollment
Levels of bound mucinoglycans-1, nitric oxide, and acetylheparin sulfate in peripheral blood
glycocalyx levels of the endothelium were assessed by measuring the levels of mucin polysaccharide-1, nitric oxide and acetyl heparan sulfate in peripheral blood by ELISA assay（Measure unit ng/ml）
Time frame: 0, 1, 3, 7 days after enrollment
In peripheral blood, IL-1α, IL-6, neutrophils, lymphocytes, descending Procalcin, C-reactive protein value
The ELISA method detects IL-1α and IL-6 in the blood, and records the blood neutrophils, lymphocytes, and vary in procalcin and C-reactive protein to assess the inflammatory response of ARDS(Measure unit pg/ml）
Time frame: 0, 1, 3, 7 days after enrollment
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Southeast University, China